Abstract Search

ea0098c32 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Myelodysplasia and leukemia instances after PRRT: Experience from a tertiary institution

Trikalinos, MD Nikolaos , De La Iglesia, MD Michael , Prasad MD, PhD Vikas , Amin, MD Manik , Winter, BSN, RN Kyle , Schutte MSN, FNP-C, AOCNP Justin , Kim, MD Hyun

Background: Peptide receptor radionuclide therapy (PRRT) was introduced in 2018 as one of the major advances in treatment of patients with neuroendocrine neoplasms (NENs). Initial results from the NETTER-1 trial suggested a very low percentage of secondary hematological malignancies, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We sought to confirm that data in a large institutional database. Methods: Under an institutio...

0 shares

Endocrine Abstracts

Myelodysplasia and leukemia instances after PRRT: Experience from a tertiary institution

BiosciAbstracts